DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aromasin (Exemestane) - Current Clinical Trials

 
 



Aromasin Related Clinical Trials

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer [Active, not recruiting]

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women [Terminated]

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin [Recruiting]

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer [Active, not recruiting]

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients [Recruiting]

Dendritic Cell Based Therapy for Breast Cancer Patients [Recruiting]

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer [Recruiting]

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer [Not yet recruiting]

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer [Recruiting]

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer [Active, not recruiting]

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding [Recruiting]

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer [Recruiting]

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer [Recruiting]

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2) [Recruiting]

FJE_Exemestane-RAD001-Metformin [Recruiting]

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer [Recruiting]

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease [Active, not recruiting]

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen [Active, not recruiting]

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer [Recruiting]

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer [Recruiting]

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients [Completed]

Therapeutic Estradiol and Exemestane in Treating Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer [Recruiting]

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer [Recruiting]

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Recruiting]

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer [Recruiting]

MK2206 and Anastrozole, Letrozole, Exemestane, or Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer [Recruiting]

A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer [Completed]

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis [Not yet recruiting]

Randomized Phase III Study of Exemestane (Aromasin) for 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed by Exemestane [Not yet recruiting]

Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers [Recruiting]

The Impact of Obesity and Obesity Treatments on Breast Cancer [Recruiting]

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer [Recruiting]

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer [Active, not recruiting]

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer [Recruiting]

Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer [Recruiting]

Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer [Recruiting]

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer [Recruiting]

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer [Recruiting]

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer [Not yet recruiting]

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery [Recruiting]

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer [Recruiting]

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer [Recruiting]

Aromasin vs Arimidex Study As Initial Hormonal Therapy in Postmenopausal Women With Advanced/Recurrent Breast Cancer [Recruiting]

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM2) [Recruiting]

Exemestane or Anastrozole in Treating Postmenopausal Women With Hormone Receptor-Positive Primary Breast Cancer [Active, not recruiting]

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer [Recruiting]

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With Breast Cancer [Recruiting]

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer [Active, not recruiting]

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer [Active, not recruiting]

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer [Active, not recruiting]

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI) [Recruiting]

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen [Active, not recruiting]

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer [Not yet recruiting]

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer [Completed]

Tamoxifen Citrate Alone or Ovarian Function Suppression and Tamoxifen Citrate or Exemestane in Treating Premenopausal Women Who Have Undergone Surgery for Breast Cancer [Recruiting]

Amgen Protocol No. 20060362 - A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer [Recruiting]

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer [Active, not recruiting]

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer [Active, not recruiting]

Exemestane in Treating Postmenopausal Women at High Risk for Invasive Breast Cancer [Recruiting]

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer [Withdrawn]

Exemestane and Raloxifene in Treating Postmenopausal Women With a History of Ductal Carcinoma in Situ, Stage I, Stage II, or Stage III Breast Cancer [Active, not recruiting]

24 Months of Exemestane or Letrozole to Treat Breast Cancer [Recruiting]

Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer [Recruiting]

Aromasin® Non-Interventional Study Of Early Invasive Breast Cancer Patients In China [Recruiting]

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients [Active, not recruiting]

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer [Recruiting]

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer [Recruiting]

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD [Recruiting]

Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors [Recruiting]

Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer And Who Are Receiving Exemestane on Clinical Trial CAN-NCIC-MAP3 [Recruiting]

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer [Not yet recruiting]

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer [Recruiting]

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer [Recruiting]

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer [Recruiting]

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer [Recruiting]

Exemestane and Cyclophosphamide for Metastatic Breast Cancer [Recruiting]

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer [Recruiting]

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab [Recruiting]

Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer [Not yet recruiting]

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer [Recruiting]

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors [Recruiting]

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. [Recruiting]

Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer [Recruiting]

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer [Recruiting]

Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane [Completed]

Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer [Completed]

Aromatase Inhibitor Clinical Trial [Recruiting]

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer [Recruiting]

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy [Recruiting]

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer [Recruiting]

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Women With Hormone Receptor-Positive Breast Cancer That Can be Removed by Surgery [Recruiting]

Second-Line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer [Recruiting]

Combination Chemotherapy and Surgery in Treating Patients With Stage II or Stage III Breast Cancer

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer [Recruiting]

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients [Recruiting]

Effect of Aromatase Inhibitors on Bones and Genes [Recruiting]

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG-2402 [Recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014